phase iii trial of denosumab for breast cancer risk reduction in brca1 carriers
Published 3 years ago • 154 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
34:37
denosumab study for preventing breast cancer in brca1
-
8:37
brca1 and brca2 mutations & cancer (types of cancer, and who’s most at risk)
-
4:24
the latest treatment options for brca-mutated breast cancer
-
4:09
doctor explains brca1 & brca2 genetic testing for inherited breast and ovarian cancer...
-
53:17
brca-positive early-stage breast cancer: treatment and testing
-
10:52
understanding brca1 and brca2: what these mutations mean for breast cancer risk
-
7:18
my genetic testing results - brca1/brca2 (triple-negative breast cancer survivor)
-
7:08
living with the brca2 gene mutation
-
5:49
the role of brca1 in dna damage response
-
58:28
updates on the treatment of brca-associated breast cancer
-
4:39
brca1 and brca2 mutation testing in young women with breast cancer
-
2:21
a study of talazoparib in somatic brca1/2 mutant mbc identified by cfdna or tumor tissue genotyping
-
8:09
new research for brca-positive breast cancer patients
-
6:41
a guide to brca1 and brca2 gene mutations in hereditary breast and ovarian cancer
-
2:25
reducing risk in residual breast cancer
-
1:46
combination of veliparib and chemotherapy in brca-positive breast cancer
-
1:01:28
emerging options for brca-mutated breast cancer treatment
-
6:27
brca across tumour types
-
35:40
understanding brca 1/2 cancer risk | dana-farber cancer institute
-
1:47
an overview of the ma17r trial in breast cancer
-
1:43
dr. lori pierce on the impact of brca1/2 mutations on breast cancer treatment decisions
-
3:14
parp inhibitor staves off recurrence in early brca-mutant breast cancer - medpage today